Principal Securities, Inc. Biotechnology

Principal Securities, Inc.

$4.44 Trillion
Q4 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
RGNX Regenxbio Inc.	$342M	$1.46 Million 0.0% of portfolio	189	Q1 2024 Added 220.34%
NTRB Nutri Band Inc.	$51.7M	$1.41 Million 0.0% of portfolio	300	Q1 2024 New
VERV Verve Therapeutics, Inc.	$316M	$1.39 Million 0.0% of portfolio	246	Q3 2024 Added 48.19%
RNA Avidity Biosciences, Inc.	$1.7B	$1.31 Million 0.0% of portfolio	45	Q4 2024 Added 25.0%
HUMA Humacyte, Inc.	$207M	$1.26 Million 0.0% of portfolio	250	Q4 2024 Reduced 50.0%
KRYS Krystal Biotech, Inc.	$4.69B	$1.1 Million 0.0% of portfolio	7	Q4 2024 New
BBIO Bridge Bio Pharma, Inc.	$5.4B	$1.04 Million 0.0% of portfolio	38	Q3 2024 Reduced 73.05%
NTLA Intellia Therapeutics, Inc.	$638M	$1.04 Million 0.0% of portfolio	89	Q4 2024 Reduced 84.36%
OMGA Omega Therapeutics, Inc.	$957K	$1.02 Million 0.0% of portfolio	1,370	Q3 2024 New
CVAC Cure Vac N.V.	$525M	$992,000 0.0% of portfolio	291	Q3 2024 Added 64.41%
ARCT Arcturus Therapeutics Holdings Inc.	$319M	$933,000 0.0% of portfolio	55	Q2 2024 Reduced 15.38%
ASND Ascendis Pharma A/S	$8.81B	$826,000 0.0% of portfolio	6	Q3 2024 New
AGIO Agios Pharmaceuticals, Inc.	$1.69B	$822,000 0.0% of portfolio	25	Q4 2024 New
ABUS Arbutus Biopharma Corp	$490M	$752,000 0.0% of portfolio	230	Q4 2024 New
EWTX Edgewise Therapeutics, Inc.	$1.48B	$721,000 0.0% of portfolio	27	Q3 2024 New
WVE Wave Life Sciences Ltd.	$782M	$717,000 0.0% of portfolio	58	Q4 2024 Added 28.89%
AXSM Axsome Therapeutics, Inc.	$5.22B	$677,000 0.0% of portfolio	8	Q3 2024 Added 166.67%
PTGX Protagonist Therapeutics, Inc	$2.43B	$463,000 0.0% of portfolio	12	Q4 2024 Reduced 20.0%
DSGN Design Therapeutics, Inc.	$234M	$457,000 0.0% of portfolio	74	Q2 2024 New
ADMA Adma Biologics, Inc.	$3.98B	$377,000 0.0% of portfolio	22	Q3 2024 New
ARWR Arrowhead Pharmaceuticals, Inc.	$1.46B	$376,000 0.0% of portfolio	20	Q4 2024 Reduced 75.0%
RVMD Revolution Medicines, Inc.	$3.34B	$350,000 0.0% of portfolio	8	Q4 2024 New
EDIT Editas Medicine, Inc.	$89.4M	$311,000 0.0% of portfolio	245	Q3 2024 Added 25.64%
RARE Ultragenyx Pharmaceutical Inc.	$2.72B	$294,000 0.0% of portfolio	7	Q4 2024 New
MRUS Merus N.V.	$2.06B	$294,000 0.0% of portfolio	7	Q3 2024 New
DNLI Denali Therapeutics Inc.	$1.91B	$285,000 0.0% of portfolio	14	Q4 2024 Reduced 39.13%
ACAD Acadia Pharmaceuticals Inc	$2.78B	$239,000 0.0% of portfolio	13	Q4 2024 New
ACLX Arcellx, Inc.	$3B	$230,000 0.0% of portfolio	3	Q4 2024 Reduced 40.0%
SRRK Scholar Rock Holding Corp	$1.72B	$173,000 0.0% of portfolio	4	Q4 2024 New
VRDN Viridian Therapeutics, Inc.\De	$585M	$173,000 0.0% of portfolio	9	Q4 2024 New
KURA Kura Oncology, Inc.	$478M	$157,000 0.0% of portfolio	18	Q3 2024 Added 125.0%
NVAX Novavax Inc	$568M	$121,000 0.0% of portfolio	15	Q4 2024 New
VIR Vir Biotechnology, Inc.	$885M	$117,000 0.0% of portfolio	16	Q4 2024 New
MREO Mereo Biopharma Group PLC	$297M	$112,000 0.0% of portfolio	32	Q4 2024 New
CLLS Cellectis S.A.	$58.7M	$94,000 0.0% of portfolio	52	Q4 2024 New
SAVA Cassava Sciences Inc	$68.2M	$59,000 0.0% of portfolio	25	Q4 2024 Reduced 50.0%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Principal Securities, Inc. with notifications on news.